Has Majid Tayyarah, MD received payments from drug or device companies?

Yes. Drug and device makers reported $9,786 in general payments to Majid Tayyarah, MD across 83 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Majid Tayyarah, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Majid Tayyarah, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Majid Tayyarah, MD

Vascular Surgery · Fontana, CANPI 1932276953

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $8,345 of the $9,786 with a category attached, or 85.3%. 13 manufacturers reported payments, led by Medtronic at 28.6% of the total.

$9,786in general payments, 2019–2025

Across 83 payments — averaging $117.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Medtronic$3K
W. L. Gore & Associates, Inc.$3K
Penumbra, Inc.$2K
Endologix LLC$913
Silk Road Medical, Inc.$319
Abbott$174
plus $546 from 7 others

What the payments were for

Travel & lodging$1,39114%
Food & beverage$8,34585%
Education$501%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Medtronic(2 entities)	23	$2,799
W. L. Gore & Associates, Inc.	30	$2,717
Penumbra, Inc.	11	$2,318
Endologix LLC	4	$913
Silk Road Medical, Inc.	4	$319
Abbott	2	$174
Terumo Medical Corporation	3	$172
Biotronik Inc.	1	$138
Centerline Biomedical Inc.	1	$64
Baxter Healthcare	1	$59
Lemaitre Vascular, Inc.	1	$56
Mallinckrodt Hospital Products Inc.	1	$30
Cook Medical LLC	1	$27

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Indigo System$2,137
ENDURANT IIS$1,256
C3 Delivery System$1,110
Endurant$748
Ovation$570
Alto Abdominal Stent Graft System$293
ENROUTE Transcarotid Neuroprotection System$269
ENHANCE Transcarotid Peripheral Access Kit$269
GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis$256
GORE TAG Thoracic Branch Endoprosthesis$218
Abre$176
EXCLUDER AAA Endoprosthesis$154
SilverHawk$150
JETi Peripheral Catheter$146
Valiant Navion$145
ENROUTE Transcarotid Stent System$142
ENROUTE 0.014 Guidewire$142
Valiant Captivia$141
GORE VIABAHN VBX Balloon Expandable Endo$140
Oscar$138

How this compares

$9,786 in reported general payments places this provider in the 70th percentile of 519 vascular surgery providers in California.

See all vascular surgery providers in California →

Medicare billing

Part B allowed, 2024

$1,938

Medicare patients

Services billed

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
PradaxaDabigatran Etexilate Mesylate	11	$2,327
Lidocaine-PrilocaineLidocaine/Prilocaine	40	$1,146
Cilostazol	41	$1,096
ClopidogrelClopidogrel Bisulfate	32	$617
Atorvastatin Calcium	45	$530
Gabapentin	40	$457

Paid to pharmacies, not to this prescriber.

Other vascular surgery in Fontana

Son DuongFountain Valley$503K
Venita ChandraPalo Alto$488K
Sukgu HanLos Angeles$477K
Leigh Ann ObanionFresno$469K
Trevor DerderianRancho Mirage$359K
Karthikeshwar KasirajanPalo Alto$349K
Johnathon RolloLos Angeles$337K
Melissa LojaFairfield$272K
Jason LeePalo Alto$228K
John LaneSan Diego$212K

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →